Literature DB >> 6838651

Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin.

G Leyhausen, D K Schuster, P Vaith, R K Zahn, H Umezawa, D Falke, W E Müller.   

Abstract

Bestatin was found to be a competitive inhibitor (with respect to the Leu-NA substrate) not only of the isolated microsomal and cytosolic leucine aminopeptidases (Leu-APm and Leu-APc) but also of the aminopeptidases (APs) present in membrane preparations (from mouse liver) and on the cell surface of L5178Y cells. Kinetic parameters indicate that cellular AP is identical to Leu-APm. To rule out the possibility that AP-B is involved in the inhibition reactions, comparable studies with amastatin were performed. Electrophoretical studies revealed the solubilized cell membrane bound AP to co-migrate with Leu-APm in polyacrylamide gels. The activity of the separated membrane AP was inhibited by bestatin in situ. The cell membrane bound AP activity was found to be lowest in lymphocytes, higher in tumor cells and highest in bone marrow cells and macrophages. Using synchronized L5178Y cells, the AP activity changes during the cell division cycle; the lowest activity was determined during the G1-phase and 35% higher values were measured during the S/G2-phase. The fluctuation of the cell surface associated AP activity parallels with changes in the number of binding sites for bestatin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838651     DOI: 10.1016/0006-2952(83)90624-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Cryptochrome in sponges: a key molecule linking photoreception with phototransduction.

Authors:  Werner E G Müller; Heinz C Schröder; Julia S Markl; Vlad A Grebenjuk; Michael Korzhev; Renate Steffen; Xiaohong Wang
Journal:  J Histochem Cytochem       Date:  2013-08-06       Impact factor: 2.479

2.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.

Authors:  Li Su; Jiangying Cao; Yuping Jia; Xiaonan Zhang; Hao Fang; Wenfang Xu
Journal:  ACS Med Chem Lett       Date:  2012-09-21       Impact factor: 4.345

4.  Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin).

Authors:  J Yoneda; I Saiki; H Fujii; F Abe; Y Kojima; I Azuma
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

5.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  P1' Residue-Oriented Virtual Screening for Potent and Selective Phosphinic (Dehydro) Dipeptide Inhibitors of Metallo-Aminopeptidases.

Authors:  Michał Talma; Artur Mucha
Journal:  Biomolecules       Date:  2020-04-24

7.  Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions.

Authors:  Mirjana Grujić; Metka Renko
Journal:  Cancer Lett       Date:  2002-08-28       Impact factor: 8.679

Review 8.  Metallo-aminopeptidase inhibitors.

Authors:  Artur Mucha; Marcin Drag; John P Dalton; Paweł Kafarski
Journal:  Biochimie       Date:  2010-05-10       Impact factor: 4.079

Review 9.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

10.  Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro.

Authors:  I Saiki; J Murata; K Watanabe; H Fujii; F Abe; I Azuma
Journal:  Jpn J Cancer Res       Date:  1989-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.